The Scottish Medicines Consortium (SMC) has updated its advice for AstraZeneca’s Lokelma (sodium zirconium cyclosilicate [SZC]) for adult patients with hyperkalaemia in Scotland. Patients can now access SZC in the emergency care setting for the treatment of acute, life-threatening hyperkalaemia alongside standard care. SZC is already used within NHS Scotland for hyperkalaemia as outpatient care […]
